The California Workers’ Compensation Institute (CWCI) published new data regarding their independent medical reviews (IMR) medical dispute resolution program by reviewing 1.8 million IMR decisions issued from 2015 through September 2026.
Approximately 90.2% of all utilization review (UR) physician denials and modifications were upheld. In the first three quarters of 2026, 110,965 IMR letters were issued, down 3.1% from the same period last year, the first reduction since IMR volume began rebounding from a historic low in 2022. Despite the drop, the latest tally remained well above the comparable nine-month totals for 2020 through 2024.
Uphold rates varied by medical service category, ranging from 80.8% for Evaluation and Management requests to 95.2% for Acupuncture. The largest increases occurred in Surgery, where the uphold rate climbed from 86.1% to 88.8%, and Psychiatric Services, where the rate rose from 81.3% to 83.1%.
Pharmaceutical disputes continued to generate the largest share of IMR decisions at 30.8%, with physical therapy coming in second at 13.2% and injections at 12.8%. Among the pharmaceutical IMRs, opioid disputes continued to decline, falling to just 16.7% of all prescription drug decisions, as the uphold rate for opioid denials and modifications hit an all-time high of 95.7%.
Dermatological drugs accounted for 25.9% of the pharmaceutical IMRs – the highest share and more than double their 12.3% share in 2018. Musculoskeletal drugs ranked second at 20.0% and had the highest uphold rate among drug categories at 98.5%. Anticonvulsants also reached a record share, increasing to 10.6% of the pharmaceutical IMRs.
CWCI’s review also noted the continued concentration of IMR activity among a relatively small group of physicians. The top 10% of physicians named in decision letters during the 12 months ending September 2026 (789 providers) accounted for 84.5% of all disputed service requests and the top 1% (79 providers) accounted for 41.9%.






